Clínic Hospital
If you are the contact person for this centre and you wish to make any changes, please contact us.
Head of the Cardiology Department at the Hospital Clínic de Barcelona and researcher at the National Centre for Cardiovascular Research (CNIC) and at the August Pi Sunyer Biomedical Research Institute (IDIBAPS)
Neurologist at the Hospital Clínic in Barcelona
Head of Microbiology at Hospital Clínic in Barcelona, associate professor at the University of Barcelona, and researcher at ISGlobal Barcelona
Psychiatrist and researcher at the Bipolar and Depressive Disorders Unit of the Hospital Clínic de Barcelona
Head of the Arrhythmias and Physical Activity research group at IDIBAPS, cardiac electrophysiologist at Hospital Clínic Barcelona, associate professor of Medicine at the University of Barcelona and researcher at CIBERCV.
Professor of Psychiatry at the University of Barcelona, Head of the Psychiatry and Psychology Department at Hospital Clínic in Barcelona, and researcher at the Biomedical Research Centre in Mental Health (CIBERSAM)
Psychiatrist and researcher at the Depressive and Bipolar Disorders Unit of the Hospital Clínic de Barcelona
Assistant Doctor of Psychiatry and postdoctoral researcher at the Bipolar and Depressive Disorders Unit of the Psychiatry and Psychology Department of the Hospital Clínic de Barcelona.
Professor of Medicine at the University of Barcelona and coordinator of the Central Sensitisation Unit at the Hospital Clínic de Barcelona.
Research Professor at IDIBAPS-Hospital Clínic de Barcelona and Scientific Director of CIBEREHD - Carlos III Health Institute
Procrastination in a sample of more than 3,500 students was associated with the development of both mental and physical health problems nine months later, according to a study conducted at several universities in Sweden. The results are published in the journal JAMA Network Open.
Two preclinical studies published in the journal Science have introduced new bioengineered modifications to CAR-T cells in an attempt to make them more potent and safer in their anti-tumour action. These variations allow their activity to be enhanced only in the vicinity of the tumour or their actions to be regulated on demand.
Two studies published in the journal Nature Communications have found specific characteristics in the microbiota of people with depression, including populations of different ethnicities and habits.
A few weeks ago, a press release from the Biogen and Eisai companies reported significant results from their lecanemab antibody for the treatment of early-stage Alzheimer's. The data from the phase 3 trial are now published in the New England Journal of Medicine, coinciding with the CTAD conference on Alzheimer's disease clinical trials in San Francisco. Data from the phase 3 clinical trial are now published in the New England Journal of Medicine, coinciding with the 15th CTAD Alzheimer's disease clinical trials conference in San Francisco.
A pioneering phase 1 clinical trial has tested a type of cancer immunotherapy. Researchers have modified patients' own T-lymphocyte receptors using the CRISPR tool to direct them against specific targets on their own tumours. The results are published in the journal Nature.
A phase 2 clinical trial has examined the use of the hallucinogen psilocybin in different amounts for the treatment of resistant depression. The results are published in the New England Journal of Medicine.
A Canadian study published in the Canadian Journal of Cardiology found that adjusted mortality from myocardial infarction is not different between men and women aged 18-55 years, but hospital readmission in the following year is higher in women.
Research among more than 7,000 US adults shows small changes in extraversion, agreeableness, openness to change and conscientiousness between the period before the covid-19 pandemic and the year 2022, especially in younger people. The study is published in PLOS ONE.
Psychological distress, including depression, anxiety, worry, perceived stress and loneliness, prior to covid-19 infection was associated with an increased risk of persistent covid, according to research published in JAMA Psychiatry.
US researchers have designed an intranasal vaccination device that is capable of delivering immunising proteins through the mucosal surface. The research, published in Science Translational Medicine, shows that strong antibody responses against viruses such as HIV and SARS-CoV-2 have been achieved in mice and non-human primates.